%0 Journal Article
%T Identifying the incidence of rash, Stevens-Johnson syndrome and toxic
epidermal necrolysis in patients taking lamotrigine: a systematic review of 122
randomized controlled trials
%A Kyle T. Amber
%A Romi Bloom
%J Archive of "Anais Brasileiros de Dermatologia".
%D 2017
%R 10.1590/abd1806-4841.20175070
%X Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%
%K Adverse drug reaction reporting systems
%K Drug eruptions
%K Drug Toxicity
%K Stevens-Johnson Syndrome
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312199/